MiNK Therapeutics, Inc. (INKT)

Develops T cell-based immunotherapies for cancer treatment, focusing on enhancing immune responses against tumors.

INKT Stock Quote

Company Report

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company based in New York, New York, specializes in the discovery, development, and commercialization of innovative allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies. Formerly known as AgenTus Therapeutics, Inc., the company rebranded to MiNK Therapeutics, Inc. in its pursuit of pioneering treatments for cancer and immune-mediated diseases. MiNK Therapeutics is at the forefront of advancing AGENT-797, its lead product candidate in Phase 1 clinical trials.

AGENT-797 represents a promising off-the-shelf, allogeneic iNKT cell therapy designed to address various forms of myeloma. This innovative therapy underscores MiNK Therapeutics' commitment to leveraging cutting-edge biopharmaceutical technologies to improve patient outcomes in oncology and beyond. With a strong emphasis on scientific rigor and therapeutic innovation, MiNK Therapeutics aims to redefine treatment standards in the field of immune-mediated diseases.

Founded in 2017 and operating as a subsidiary of Agenus Inc., MiNK Therapeutics benefits from strategic collaborations and a robust research framework. The company continues to expand its pipeline and explore novel applications of iNKT cell therapies, positioning itself as a leader in the rapidly evolving landscape of biopharmaceutical innovation.

INKT EPS Chart

INKT Revenue Chart

Stock Research

ORMP TGAN DHCA NVGS BA PAA SHAK

INKT Chart

View interactive chart for INKT

INKT Profile

INKT News

Analyst Ratings